Cost-benefit analyses.
Cost-benefit analyses.
复制标题
成本效益分析。
DOI：
10.1007/978-3-540-31611-4_11
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Regula E Bürki
中科院分区：
文献类型：
--
作者：
R. Brun Del Re;Regula E Bürki
只有少数几个欧洲国家(瑞士、法国、波兰、比利时和德国的一些当地项目)的微创乳腺活检(MIBB)是由医疗保险报销的。公共卫生当局要求提供详细的成本估计和计算以及费力、昂贵的评估程序，作为决定的基础，然后要求保险公司提供补偿。在欧洲，保险公司需要支付哪些服务通常是公共政策问题。然而，以下审议同样适用于与其他地方的私营或政府保险公司的直接谈判。以下部分分析了在预测特定地区或国家的微创乳腺活检的数量和成本时要考虑的普遍接受的因素和数据。这包括乳房X光检查的频率和情况、对乳房X光检查异常发现的召回率，以及为澄清这些异常发现而进行的不同后续检查和活组织检查的类型和分布。正在制定的新程序和医疗保险实体的报销模式改变了不同活检程序的分布。
Only in a few European countries (Switzerland, France, Poland, Belgium, and some local projects in Germany) are minimally invasive breast biopsies (MIBB) reimbursed by health insurance. Public health authorities ask for detailed estimates and calculation of costs as well as laborious, expensive evaluation procedures as the basis for decision making before obliging insurance to provide reimbursement. In Europe, which services insurance companies are required to pay is generally a matter of public policy. However, the following deliberations apply equally to direct negotiations with private or governmental insurers elsewhere. The following sections analyze the generally accepted factors and data to be considered when predicting the numbers and cost of minimally invasive breast biopsy in a given region or country. These include the frequency and circumstances of mammography, the recall rate for abnormal findings on mammography, and the type and distribution of the different follow-up investigations and biopsy procedures performed to clarify these abnormal findings. The distribution of the different biopsy procedures is altered by new procedures being developed and by the pattern of reimbursement on the part of the health insurance entities.